Download

full announcement

UK
04 Jul 2016 10:58 CET

Novo Nordisk invests DKK 400 million in an expanded production plant in Kalundborg

Bagsværd, Denmark, 4 July 2016 - Novo Nordisk is investing 400 million Danish kroner in a 500 m2 extension of the world's largest insulin production plant in Kalundborg. 

"The expansion of our production plant highlights our ambition to continue strengthening our presence in Kalundborg. The new facilities will give us greater flexibility and enable the installation of equipment that will enhance efficiency and increase the long-term production capacity of the plant," says Michael Hallgren, senior vice president and head of production in Kalundborg.

Established in 1969, the Kalundborg production site today covers a total area of 1.1 million square metres. With its 3,400 employees, Novo Nordisk Kalundborg is a cornerstone of Novo Nordisk's global production and produces 50% of the world's insulin as well as a range of biopharmaceutical products.

Groundbreaking for the plant extension will take place today and the extension is expected to be completed at the end of 2018.

 

Further information

Media    
Mette Kruse Danielsen +45 30793883 mkd@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com